Managed Health Care

Progyny

Progyny released FY2026 Q1 earnings on May 7 After-Market EST, actual revenue USD 328.5 M (forecast USD 326.51 M), actual EPS USD 0.29 (forecast USD 0.2563)

Progyny to Release FY2026 Q1 Earnings on May 7 After-Market (EST), Forecast Revenue USD 326.51 M, EPS USD 0.2563

Progyny released FY2025 Q4 earnings on February 26 After-Market EST, actual revenue USD 318.4 M (forecast USD 314.26 M), actual EPS USD 0.14 (forecast USD 0.1473)

Progyny released FY2025 Annual Earnings on February 26 After-Market EST, actual revenue USD 1.289 B (forecast USD 1.278 B), actual EPS USD 0.65 (forecast USD 0.6585)

Progyny to Release FY2025 Q4 Earnings on February 26 After-Market (EST), Forecast Revenue USD 314.26 M, EPS USD 0.1473

Progyny to Discuss Updated Financial Forecasts at JP Morgan Healthcare Conference

Progyny Inc CFO Reports Sale of Company Common Stock

Cantor Fitzgerald Analyst Reiterates Buy Rating on Progyny

Progyny released FY2025 9 Months earnings on November 6 After-Market (EST), actual revenue USD 970.26 M, actual EPS USD 0.51

Progyny released FY2025 Q3 earnings on November 6 After-Market EST, actual revenue USD 313.35 M (forecast USD 299.23 M), actual EPS USD 0.15 (forecast USD 0.1267)

Progyny to Release FY2025 Q3 Earnings on November 6 After-Market EST, Forecast Revenue USD 299.23 M, EPS USD 0.1267

Analyst Upgrades Progyny Stock Rating to Buy

Progyny released FY2025 Semi-Annual earnings on August 8 After-Market EST, actual revenue USD 656.91 M, actual EPS USD 0.3599

Progyny released FY2025 Q2 earnings on August 7 After-Market EST, actual revenue USD 332.87 M (forecast USD 320.12 M), actual EPS USD 0.19 (forecast USD 0.1689)

Progyny to release FY2025 Q2 earnings on August 7 After-Market EST, forecast revenue USD 320.12 M, EPS USD 0.1689

Progyny Receives Upgrades from Multiple Research Firms

Progyny Inc. Partners with ŌURA to Enhance Women's Health

Leerink Partners Upgrades Progyny Stock Rating

Progyny Expects Q2 Results to Exceed Guidance, Enhances Financial Flexibility

Progyny Inc. to Report 2025 Q2 Financial Results

Freecast

Cuprina

U-BX Tech

HORIZON SPACE ACQUISITION II CORP COM USD0.0001 30/03/2026(SUB/RIGHTS)

Defiance Pure Space Dly 2X Strat ETF

VS MEDIA

Everbright Digital

Park Ha Biological Tech

Friedman Industries

Defiance Daily Target 2X Short ASTS ETF

PGNY

Analysts have raised Progyny, Inc.'s 12-month average price target from $29.55 to $29.73, implying a 13% upside based on the June 1 closing price. The consensus rating remains 'Buy' among 11 covering analysts, with 10 buys and 1 hold. Price forecasts range from $26 to $31 per share.

TradingView

Factset Research

Progyny, Inc. Stock 12‑Month Price Target Raised to $29.73, Implies 13% Upside

A new Progyny study reveals that 78% of patients value strong human connections with healthcare providers, believing it enhances treatment outcomes. Furthermore, 85% emphasize the need for healthcare advocates to improve their overall well-being, highlighting the increasing demand for personalized care and emotional support in the digital healthcare landscape.

Unusual Whales

New Progyny Study Shows Growing Demand for Human Guidance in an Increasingly Digital Healthcare System

Progyny (NasdaqGS:PGNY) has announced a US$200 million share repurchase program, signaling management's confidence in the company's cash position and growth potential. This buyback could impact shareholder value, ownership concentration, and earnings per share. Investors should consider how this decision aligns with their preferences for income versus reinvestment, as it may limit funds available for growth initiatives. Monitoring the execution of the buyback and its effects on share count and capital needs will be crucial for assessing Progyny's future performance.

Simplywall

Progyny Buyback Raises Questions On Capital Returns And Growth Plans

STUB

Top Wall Street analysts upgraded STUB, PGNY, AMT, and BAP stocks, raising their price targets significantly. Guggenheim upgraded Stubhub from Neutral to Buy with a target of $12.5. Canaccord Genuity upgraded Progyny to Buy with a target of $30. Bernstein upgraded American Tower to Outperform with a target of $207. HSBC upgraded Credicorp to Buy with a target of $350.

benzinga_article

American Tower

Credicorp

Stubhub - CL

This Stubhub Analyst Turns Bullish; Here Are Top 4 Upgrades For Tuesday

Progyny, Inc. to Present at BofA Securities 2026 Health Care Conference | PGNY Stock News

StockTitan

Bank of America

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH INT NON CUM PFD QQ

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '5'

BANK OF AMERICA CORPORATION 7.25% NON-CUM PERP CONV PFD SER L

BANK OF AMERICA CORPORATION 5.875%NON CUM DEP SHS REP1/1000TH SER HH

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '2'

BANK OF AMERICA CORPORATION 5% DEP SHS REPR 1/1000TH NON CUM PFD LL

BANK OF AMERICA CORPORATION DEP SHARES REP 1/1000TH PERP PFD SER 'E'

BANK OF AMERICA CORPORATION INCOME CAPITAL OBLIG NTS DUE 15/12/2066

BANK OF AMERICA CORPORATION 4.375% DP SH RP 1/1000TH IN NON CU PF NN

BANK OF AMERICA CORPORATION DEP SH REP 1/1200TH PRF SER 1 USD25

BANK OF AMERICA CORPORATION 5.375%DEP SHS REP 1/1000TH NON CUM SR KK

BANK OF AMERICA CORPORATION 6%NON CUM DEP SHS EACH REP 1/1000 SER GG

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200 PFD SER 4 USD25

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH NON CUM PFD SER SS

BANK OF AMERICA CORPORATION 4.125%DEP SH REP 1/1000 PFD SER PP USD25

Bank of America Corp

Progyny, Inc. to Present at BofA Securities 2026 Health Care Conference | PGNY Stock News

Zacks Research upgraded Progyny (NASDAQ: PGNY) from a "hold" to a "strong-buy" rating. Other analysts have also given mixed ratings, with one strong buy, nine buys, and three holds. The stock has seen a 23.8% increase, opening at $23.72, with a market cap of $1.86 billion. Progyny reported Q1 earnings of $0.29 per share, exceeding estimates, but revenue was down 26.4% year-over-year. Institutional investors hold 94.93% of the stock, and recent insider activity includes the sale of shares by EVP Allison Swartz.

Market Beat

JPMorgan Chase

Truist Financial

Jefferies Financial

CAITONG SECURITIES

Federated Hermes

Versant Media

Covestro AG

JPMORGAN CHASE & CO. 4.20% DEP SHS REPSTG 1/400TH PFD SER MM

JPMORGAN CHASE & CO. 6%NON CUM DEP SHS REP 1/400TH PFD SER EE

JPMORGAN CHASE & CO. DEP REP 1/400TH (5.75% NON CUM PFD DD)

JPMORGAN CHASE & CO. 4.625% DEP SH RE 1/400TH INT NO CU PF LL

JPMorgan Chase & Co.

JPMORGAN CHASE & CO. 4.55% DEP SHS REPSTG 1/400TH PFD SER JJ

JPMORGAN CHASE & CO. 4.75 DEP SHS REP 1/400 NCUM PFD SR GG

Versant Media Group - WI

Progyny (NASDAQ:PGNY) Raised to Strong-Buy at Zacks Research

Progyny, Inc. reported record Q1 revenue, exceeding guidance with a 1.4% year-over-year growth, and raised full-year profitability targets. Adjusted EBITDA is projected between $232 million and $244 million, with net income and EPS also increased. The company emphasized strong member engagement and cash generation, ending the quarter debt-free with $225 million in cash. Progyny completed a $200 million share buyback and is evaluating a new repurchase program. Despite transition client impacts, the sales pipeline shows positive momentum, and a third-party study validates the effectiveness of Progyny's programs.

Tip Ranks

Progyny Earnings Call Signals Confident, Profitable Growth

INOD

RKLB

FLNC

AKAM

PHOE

EOSE

MRAM

Innodata(INOD) rose 86%, with a trading turnover 1.6 Billion USD, and a year-to-date rose 66.6%. Rackspace Tech(RXT) rose 55.97%, with a trading turnover 760.6 Million USD, and a year-to-date rose 465.5%. Rocket Lab(RKLB) rose 34.22%, with a trading turnover 7.8 Billion USD, and a year-to-date rose 51.2%.

Top Gainers&Losers

Innodata

Rackspace Tech

Rocket Lab

AMN Healthcare Services

Fluence Energy

Akamai Tech

Phoenix Asia

EOS Energy Enterprises

Everspin Tech

Top 10 US Stock Gainers (5.8)

Earnings Watch

Progyny | 10-Q: FY2026 Q1 Revenue Beats Estimate at USD 328.5 M

Progyny, Inc. reported its first-quarter 2026 results, showing revenue of $328.5M, a net income of $24.23M, and diluted EPS of $0.29, compared to $324.04M, $15.06M, and $0.17 in the same quarter last year. Revenue increased by 1.4% year-over-year, with membership growing to approximately 7.2M. The gross margin improved to 25.3%. The company also launched new women's health offerings and completed a $200M share repurchase program.

Progyny, Inc. 1Q 2026: Revenue $328.5M, EPS $0.29— 10-Q Summary

Progyny(PGNY.US)

Progyny, Inc. Stock 12‑Month Price Target Raised to $29.73, Implies 13% Upside

New Progyny Study Shows Growing Demand for Human Guidance in an Increasingly Digital Healthcare System

Progyny Buyback Raises Questions On Capital Returns And Growth Plans

This Stubhub Analyst Turns Bullish; Here Are Top 4 Upgrades For Tuesday

Progyny, Inc. to Present at BofA Securities 2026 Health Care Conference | PGNY Stock News

Progyny (NASDAQ:PGNY) Raised to Strong-Buy at Zacks Research

Progyny Earnings Call Signals Confident, Profitable Growth

Top 10 US Stock Gainers (5.8)

Progyny | 10-Q: FY2026 Q1 Revenue Beats Estimate at USD 328.5 M

Progyny, Inc. 1Q 2026: Revenue $328.5M, EPS $0.29— 10-Q Summary